Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

SCLC, Limited Stage 1Neuroblastoma 1Neoplasms 1Lung Neoplasms 1Heart Failure 1Carcinoma, Non-Small-Cell Lung 1Arrhythmias, Cardiac 1Anemia 1

Interventions

Control Groups 2Atorvastatin 2sacubitril and valsartan sodium hydrate drug combination 1pertuzumab 1nicotinamide-beta-riboside 1empagliflozin 1dapagliflozin 1candesartan 1Trastuzumab 1Sodium Chloride 1Simendan 1Pyruvic Acid 1Population Groups 1Ogivri 1Metoprolol 1Hydroxymethylglutaryl-CoA Reductase Inhibitors 1Eplerenone 1Carvedilol 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Heart Failure × Population Groups × Clear all
NCT06092606 2023-10-23

A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients

Monyan Pharmaceutical (Shanghai) Co., Ltd.

Phase 2 Unknown
90 enrolled

Arrhythmias, Cardiac, Heart Failure, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡